MANNKIND CORP Increase (Decrease) in Deferred Charges
MANNKIND CORP (MNKD) reported Increase (Decrease) in Deferred Charges of -$13.54 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredCharges · last filed 2019-02-26
- MANNKIND CORP increase (decrease) in deferred charges for the quarter ending 2016-12-31 was $0.00.
- MANNKIND CORP increase (decrease) in deferred charges for the quarter ending 2015-12-31 was $0.00.
- MANNKIND CORP increase (decrease) in deferred charges for the quarter ending 2015-09-30 was $2.71M.
- MANNKIND CORP increase (decrease) in deferred charges for the quarter ending 2015-06-30 was $4.58M.
- MANNKIND CORP increase (decrease) in deferred charges for fiscal 2016 was -$13.54M, a 200.00% decline from fiscal 2015.
- MANNKIND CORP increase (decrease) in deferred charges for fiscal 2015 was $13.54M.
| Period end | Increase (Decrease) in Deferred Charges 3 month | Increase (Decrease) in Deferred Charges 6 month | Increase (Decrease) in Deferred Charges 9 month | Increase (Decrease) in Deferred Charges 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$13.54M 10-K · filed 2019-02-26 | ||
| 2016-09-30 | -$13.54M 10-Q · filed 2017-11-07 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $2.71M derived: sum of 2 quarters · filed 2018-02-27 | $7.29M derived: sum of 3 quarters · filed 2018-02-27 | $13.54M 10-K · filed 2018-02-27 |
| 2015-09-30 | $2.71M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2016-11-09 | $7.29M derived: sum of 2 quarters · filed 2016-11-09 | $13.54M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $4.58M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2016-08-10 | $10.83M 10-Q/A · filed 2016-08-10 | ||
| 2015-03-31 | $6.25M 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |